NCT01862900 (OX40 Breast) is a Phase 1 clinical trial of MEDI6469 in Metastatic Breast Cancer, sponsored by Providence Health & Services.

Who is sponsoring NCT01862900?

NCT01862900 is sponsored by Providence Health & Services.

What drugs are being tested in NCT01862900?

Interventions in NCT01862900: MEDI6469.

What condition does NCT01862900 study?

NCT01862900 studies Metastatic Breast Cancer, Lung Metastases, Liver Metastases.

Is NCT01862900 still recruiting?

NCT01862900 is currently completed. Last updated 21 March 2019.

Last reviewed 2019-03-21 · How we verify

NCT01862900: OX40 Breast

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

Completed Phase 1 Last updated 21 March 2019

What this trial tests

Phase 1 trial testing MEDI6469 in Metastatic Breast Cancer in 14 participants. Completed in 15 August 2018.

Timeline

27 April 2012

Primary endpoint
17 May 2016

15 August 2018

Quick facts

Lead sponsor	Providence Health & Services
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	27 April 2012
Primary completion	17 May 2016
Estimated completion	15 August 2018
Sites	1 location across United States

Drugs / interventions tested

MEDI6469 — full drug profile →

Conditions studied

Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →
Lung Metastases — all drugs for Lung Metastases →
Liver Metastases — all drugs for Liver Metastases →

Sponsor

Providence Health & Services — full company profile →

Who can join

18 and older, any sex, with Metastatic Breast Cancer or Lung Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will test the investigational antibody, MEDI6469 (anti-OX40), in combination with stereotactic body radiation in breast cancer patients that have liver or lung metastases and have received systemic therapy and have progressive disease. The investigators hypothesize that SBRT directed at metastatic breast cancer lesions will result in a systemic anti-tumor immune system response. This amplified and directed immune response could result in anti-tumor responses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

NCT07524855 — A Study of HLD-0117 in Patients With Metastatic Breast Cancer · Phase 1 · recruiting
NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting

Other Providence Health & Services trials

Trials by the same sponsor.

NCT06175000 — Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti · Phase 2 · recruiting
NCT04987996 — GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients · Phase 2 · withdrawn
NCT05349890 — Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) · Phase 1 · active not recruiting
NCT04796584 — Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication · terminated
NCT04417699 — SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01862900 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Providence Health & Services
Last refreshed: 21 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01862900.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing